Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease: Subanalysis of the JELIS trial

Circulation Journal

Volumn 74, Issue 7, 2010, Pages 1451-1457

  Ishikawa, Yuichi ^a   Yokoyama, Mitsuhiro ^b   Saito, Yasushi ^c   Matsuzaki, Masunori ^d   Origasa, Hideki ^e   Oikawa, Shinichi ^f   Sasaki, Jun ^g   Hishida, Hitoshi ^h   Itakura, Hiroshige ⁱ   Kita, Toru ^j   Kitabatake, Akira ^k   Nakaya, Noriaki ^l   Sakata, Toshiie ^m   Shimada, Kazuyuki ⁿ   Shirato, Kunio ^o   Matsuzawa, Yuji ^p  

^a Kakogawa Municipal Hospital   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^h FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ IBARAKI CHRISTIAN UNIVERSITY   (Japan)

^j KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^k Hiraoka Hospital   (Japan)

^l Nakaya Clinic   (Japan)

^m Hisatune Hospital   (Japan)

ⁿ JICHI MEDICAL UNIVERSITY   (Japan)

^o Saito Hospital   (Japan)

^p SUMITOMO HOSPITAL   (Japan)

more..

Author keywords

Coronary artery disease; Eicosapentaenoic acid; JELIS; Peripheral artery disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; PROTECTIVE AGENT;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; JAPAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; TREATMENT OUTCOME;

ADULT; AGED; CORONARY ARTERY DISEASE; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 77954493183     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0520     Document Type: Article

References (30)

1. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
2. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, et al. Reduction in the recurrence of stroke by eicosapen-taenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial. Stroke 2008; 39: 2052-2058.
3. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140.
4. Fujiwara T, Saitoh S, Takagi S, Ohnishi H, Ohata J, Takeuchi H, et al. Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. Atherosclerosis 2004; 177: 83-88.
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45(Suppl S): S5-S67.
6. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
7. Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan epa lipid intervention study (JELIS). Am Heart J 2003; 146: 613-620.
8. Kuramochi M. Periphery arterialsclerosis. Gendai Iryo 1991; 23: 35-39.
9. Ojiro M, Yamazumi K. The Prevalence and natural history of atherosclerotic obliterance (ASO) in old-age home in Amami Island, 3 years follow study. Med J Kagoshima Univ 2000; 52: 1-6.
10. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1996; 1: 60-64.
11. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007; 71: 995-1003.
12. Qadan LR, Ahmed AA, Safar HA, Al-Bader MA, Ali AA. Prevalence of metabolic syndrome in patients with clinically advanced peripheral vascular disease. Angiology 2008; 59: 198-202.
13. Barba R, Bisbe J, Pedrajas JN, Toril J, Monte R, Munoz-Torrero JF, et al. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry. Eur J Cardiovasc Prev Rehabil 2009; 16: 457-463.
14. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009; 73: 1283-1290.
15. Hulbert AJ, Turner N, Storlien LH, Else PL. Dietary fats and membrane function: Implications for metabolism and disease. Biol Rev Camb Philos Soc 2005; 80: 155-169.
16. Nozaki S, Matsuzawa Y, Hirano K, Sakai N, Kubo M, Tarui S. Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res 1992; 62: 256-260.
17. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of ldl in dialysis patients. J Am Soc Nephrol 1999; 10: 2177-2184.
18. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents lps-induced tnf-alpha expression by preventing nf-kappab activation. J Am Coll Nutr 2004; 23: 71-78.
19. Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, et al. Purified eicosapentaenoic acid reduces small dense ldl, remnant lipoprotein particles, and c-reactive protein in metabolic syndrome. Diabetes Care 2007; 30: 144-146.
20. Tamura Y, Hirai A, Terano T, Takenaga M, Saitoh H, Tahara K, et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res 1986; 25: 461-466.
21. Kramer HJ, Stevens J, Grimminger F, Seeger W. Fish oil fatty acids and human platelets: Dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 1996; 52: 1211-1217.
22. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA 1979; 76: 944-948.
23. Terano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamura Y, et al. Effect of oral administration of highly purified eicosapen-taenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331.
24. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003; 361: 477-485.
25. Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y. Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-icosapentaenoic acid. J Atheroscler Thromb 2002; 9: 170-177.
26. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007; 191: 162-167.
27. Ueeda M, Doumei T, Takaya Y, Shinohata R, Katayama Y, Ohnishi N, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72: 1836-1843.
28. Mii S, Yamaoka T, Eguchi D, Okazaki J, Tanaka K. Perioperative use of eicosapentaenoic acid and patency of infrainguinal vein bypass: A retrospective chart review. Curr Ther Res 2007; 68: 161-174.
29. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114: 359-364.
30. Kohro T, Yamazaki T. Eicosapentaenoic acid (EPA) in reducing secondary cardiovascular events in hypercholesterolemic Japanese patients. Circ J 2009; 73: 1197-1198.